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ABSTRACT
Once metastatic disease has occurred, there is no cure for breast cancer. 
Consequently, identifying factors that promote and support breast cancer metastasis 
is critical for understanding how to pharmacologically target this process.  
Hormonally up-regulated neu-associated kinase (HUNK) is a serine/threonine 
protein kinase related to the sucrose non-fermenting-1 (Snf-1)/5’ adenosine 
monophosphate-activated protein kinase (AMPK) family of kinases. HUNK has been 
found to play a role in breast cancer metastasis. However, conflicting reports indicate 
HUNK is a metastasis promoting factor as well as an inhibiting factor. Our group 
recently provided evidence that supports the conclusion that HUNK is a metastasis 
promoting factor by showing that HUNK regulates breast cancer metastasis through 
phosphorylation of EGFR. Here, we summarize our findings and discuss their 
implications toward pharmacological targeting of HUNK in breast cancer.
Hormonally Up-regulated Neu-associated Kinase 
(HUNK) is a serine-threonine protein kinase that is a 
member of the Snf-1/AMPK protein kinase family [1]. 
HUNK is also known as metastasis associated protein 
kinase in VMR tumor family (MAK-V) [2]. Recently 
described functions and biological roles for HUNK 
include the regulation of cell survival, cell proliferation, 
and cell metabolic regulation [3-7]. Consequently, 
HUNK has been shown to play a role in human cancers 
due to its ability to regulate these cellular processes. In 
particular, a role for HUNK in breast cancer is evident, 
given that this kinase was originally isolated from the 
mouse mammary gland [1]. Prior studies show HUNK 
expression is regulated by Human Epidermal Growth 
Factor Receptor 2 (HER2) oncogene activation in breast 
cancer and that HUNK expression is important for tumor 
cell survival in the HER2-positive (HER2+) subtype 
of breast cancer [6, 8]. In the HER2+ subtype, HUNK 
regulates the cell survival pathways, autophagy and 
apoptosis, to promote tumor cell survival and therapeutic 
resistance to HER2 inhibitors [4, 6, 9]. Additional studies 
show that HUNK plays a role in breast cancer metastasis, 
likely in the triple-negative subtype [10-12]. Interesting, 
HUNK is reported to participate in metastasis through 
mechanisms that are independent from its activity in the 
HER2+ breast cancer subtype. Here, we discuss HUNK’s 
role in metastasis by reviewing past publications and 
discussing our current findings, including kinase 
dependent mechanisms for HUNK in driving breast 
cancer metastasis.
In a 2009 publication, Wertheim et. al. reported 
that HUNK promotes mammary tumor metastasis using 
a MMTV-myc mammary tumor model [11]. The study 
authors crossed the MMTV-myc mouse model into a 
Hunk knockout (Hunk-/-) background and evaluated 
the resulting mice for the formation of spontaneous 
metastasis. They found that MMTV-myc;Hunk-/- mice 
had reduced lung metastasis compared to MMTV-
myc;Hunk wildtype (Hunk+/+) mice. The study authors 
then generated tumor cell lines from mammary tumors 
isolated from the MMTV-myc;Hunk+/+ and MMTV-
myc;Hunk-/- mice. Tumor cells from the MMTV-
myc;Hunk-/- mice were further engineered to express 
either a wildtype (WT) Hunk or a kinase inactive Hunk 
(K91M). When tested in transwell migration and invasion 
assays, MMTV-myc;Hunk-/-, WT Hunk expressing cells 
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migrated more than MMTV-myc;Hunk-/-, K91M Hunk 
cells. Furthermore, the study authors demonstrate that 
re-expression of K91M Hunk in MMTV-myc;Hunk-/- 
derived metastatic cell lines failed to rescue metastasis by 
orthotopic xenograft assay, compared to when WT Hunk 
was re-expressed. Taken together, these results suggest 
that Hunk/HUNK kinase activity is important for the 
metastatic process. However, this study did not identify 
direct substrates of Hunk/HUNK that were dependent on 
kinase activity for metastasis.
In contradiction to this first publication, a second 
paper published in 2010 by Quintela-Fandino et. al. 
reported that HUNK suppresses metastasis in basal type 
breast cancers [12]. This group used the human basal-type 
breast cancer cell lines, MDA MB 468 and MDA MB 
231 cells, to show that exogenous expression of HUNK in 
these cell lines suppresses transwell invasion as well as in 
vivo metastasis. The study authors describe a mechanism 
whereby HUNK binds to cofilin-1 (CFL-1) to prevent the 
dephosphorylation of CFL-1 by protein phosphatase 2A 
(PP2A), maintaining CFL-1 in a phosphorylated state. 
However, HUNK does not directly phosphorylate CFL-1. 
Since CFL-1 regulates actin cytoskeleton polymerization 
and CFL-1 is inactive toward this process when it is 
phosphorylated, the study authors go on to evaluate 
the effects of HUNK on cytoskeleton rearrangement 
in response to EGF stimulation [13]. Here, the authors 
engineered MDA MB 468 cells to express a vector 
control or to overexpress WT HUNK, and then treated 
each of these cell populations with EGF. The effects of 
EGF stimulation on cytoskeletal rearrangement were 
then evaluated and the authors found that WT HUNK 
expressing MDA MB 468 cells lacked the ability to 
undergo cytoskeletal rearrangement in response to EGF. 
This study neither presented a kinase dependent role for 
HUNK in metastasis nor identified a HUNK specific 
substrate that was responsible for these activities.
The two aforementioned studies differed in their 
approach to evaluating breast cancer metastasis. The 
former made use of an established genetically engineered 
mouse mammary tumor model (GEMM) and took an 
approach to deplete Hunk by gene knockout, while the 
latter focused on using human breast cancer cell lines 
and took an approach to overexpress HUNK [12, 14]. 
The argument was made that the human cell lines in the 
latter publication represent “basal” type breast cancer and 
that this difference could account for the discrepancies 
between the studies. However, gene expression studies 
suggest that the MMTV-myc GEMM is consistent with 
the human triple-negative breast cancer subtype, which 
includes basal type breast cancers [15, 16].
Consistent with the 2009 study from Wertheim et. 
al., our findings showed that HUNK is pro-metastatic. 
Separate from the two prior studies, our study showed 
that HUNK phosphorylates the epidermal growth factor 
receptor (EGFR) at threonine (T) 654 to regulate breast 
cancer metastasis, providing a discrete HUNK-kinase 
dependent mechanism for this process [10]. Our study 
used the 4T1 mouse mammary tumor cell line as well 
as two human basal breast cancer cell lines, the MDA 
MB 468 and BT20 model. Therefore, we tested a mouse 
and two human models. We took an approach to deplete 
Hunk/HUNK in these cell lines using shRNA targeting. 
We also used a pharmacological inhibitor of HUNK as 
a tool compound to modulate kinase activity [17]. In all 
three of these cell lines, HUNK depletion or inhibition 
led to an impairment of cell migration and invasion that 
was concomitant with a loss of EGFR phosphorylation at 
T654. Furthermore, HUNK downregulation or inhibition 
resulted in a decrease in mesenchymal marker expression 
and an increase in epithelial marker expression, 
suggesting that HUNK activity correlates with epithelial 
to mesenchymal transition (EMT). We also showed 
these effects in vivo using the 4T1 model where mice 
that harbored mammary tumors from Hunk-depleted 
cells had a markedly reduced number of spontaneous 
lung metastases develop compared to mice with tumors 
derived from control cells expressing a non-functional 
shRNA. Tumors that formed from the Hunk-depleted 
cells also showed a loss of EGFR phosphorylation at 
Figure 1:  4T1 in-vivo mouse model shows the pro-metastatic nature of HUNK in breast cancer. 4T1 breast cancer cells 
were injected in the mammary glands of mice then monitored for their tumor growth and metastasis. It was found that HUNK’s direct 
phosphorylation of EGFR at T654 promotes epithelial mesenchymal transition, leading to cancer metastasis. 
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T654. Based on these findings, we concluded that HUNK 
promotes breast cancer metastasis (Figure 1).
While our technical approaches did not exactly 
replicate either of the previous studies, we noted that our 
study used MDA MB 468 cells similar to the 2010 study 
by Quintela-Fandino et. al. However, our conclusions 
from the use of the MDA MB 468 cell line differed from 
this particular study. We showed that shRNA depletion 
of HUNK reduced cell migration and invasion compared 
to cells expressing a non-functional shRNA control, 
whereas the prior study showed that overexpression 
of HUNK suppresses migration and invasion [10, 12]. 
While the use of individual reagents and techniques 
could certainly be attributed to the differences in 
results, another possibility is that exogenous HUNK 
could act as a dominant negative toward endogenous 
protein. We also noted that our study did not evaluate 
CFL-1 phosphorylation or EGF modulation of actin 
cytoskeleton. We also did not re-introduce either a WT 
HUNK or K91M HUNK into our HUNK-depleted cells, 
therefore, these areas remain to be tested.
Our study significantly differed from either of the 
prior studies because we identified a direct substrate of 
HUNK that provided a mechanism for the metastatic 
behavior of the mammary tumor and breast cancer cell 
lines we tested. To date, very few HUNK substrates are 
identified [7, 10, 18, 19]. Three of the proteins identified 
as HUNK substrates; EGFR, Run domain Beclin-
1-interacting and cysteine-rich domain-containing 
protein (RUBICON), and integral membrane protein 2A 
(ITM2A), are described in the context of breast cancer 
[7, 10, 19]. A fourth protein phosphorylated by HUNK 
is dishevelled (Dsh), which has critical roles in eye and 
brain development [18]. This study was carried out using 
Xenopus laevis. Interestingly, developmental defects 
in eye and brain, or any other organ system, have not 
been reported in mouse models where Hunk is either 
genetically deleted or transgenically overexpessed [14, 
20, 21]. Consequently, additional investigation is needed 
to clarify these findings.
Future studies to evaluate known HUNK 
substrates, as well as continuing to identify new HUNK 
substrates, will greatly facilitate our understanding about 
how HUNK participates in the pathological development 
of human disease. Moreover, once a clinically relevant 
pharmacological inhibitor is developed for HUNK, 
the knowledge generated about HUNK substrates will 
greatly facilitate the pharmacological study of HUNK 
within models of human disease.
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